Archives of Industrial Biotechnology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Rapid Communication - Archives of Industrial Biotechnology (2024) Volume 8, Issue 6

Innovations in 3d cell culture systems for drug discovery.

Jack Wilson *

School of Biotechnology, University of Queensland, Australia

*Corresponding Author:
Jack Wilson
School of Biotechnology, University of Queensland, Australia
E-mail: w.jack@gmail.com

Received: 02-Dec-2024, Manuscript No. AAAIB-24-154693; Editor assigned: 03-Dec-2024, PreQC No AAAIB-24-154693 (PQ) Reviewed:17-Dec-2024, QC No. AAAIB-24-154693 Revised:24-Dec-2024, Manuscript No. AAAIB-24-154693 (R); Published:30-Dec-2024, DOI:10.35841/aaaib-8.6.245

Citation: Wilson J. Innovations in 3D cell culture systems for drug discovery. Arch Ind Biot. 2024;8(6):245

Visit for more related articles at Archives of Industrial Biotechnology

Introduction

In recent years, the field of drug discovery has undergone a transformative shift, largely driven by advancements in 3D cell culture systems. These systems, which mimic the in vivo environment more accurately than traditional 2D cultures, offer novel insights into cellular behavior, drug response, and disease progression. By providing a more realistic microenvironment, 3D cell cultures have revolutionized the way pharmaceutical companies and researchers develop new therapeutics, providing better predictions of drug efficacy and toxicity [1].

Traditional 2D cell cultures have been the foundation of drug testing for decades. However, these models often fail to replicate the complexities of human tissues, leading to limitations in predicting real-world drug responses. Cells grown on flat surfaces do not interact with each other or their environment in the same way they do in living organisms. This discrepancy has contributed to the high failure rates of drug candidates during clinical trials. In contrast, 3D cell cultures provide a more physiologically relevant platform, allowing cells to grow in a three-dimensional structure that simulates natural tissue architecture [2].

Various types of 3D cell culture models have been developed to meet the needs of different drug discovery processes. One of the most common approaches is the use of spheroids, which are clusters of cells that form a spherical structure. These spheroids exhibit cellular organization and gradients in oxygen and nutrients similar to those in solid tumors, making them ideal for cancer research. Another model gaining traction is the organoid, which is a miniature, simplified version of an organ that can replicate specific organ functions. Organoids have shown great promise in studying diseases like cystic fibrosis, Alzheimer’s, and liver fibrosis [3].

For 3D cell cultures to be truly effective, they must be supported by appropriate scaffolds and biomaterials that allow cells to grow in a more natural environment. Hydrogels, such as Matrigel and collagen, are often used as scaffolding materials to create a gel-like matrix where cells can interact with each other and the extracellular matrix. These materials not only provide structural support but also facilitate the exchange of nutrients and waste products. Innovations in synthetic biomaterials have further enhanced the customization of these cultures, allowing for precise control over stiffness, porosity, and degradation rates, which can affect cellular behaviour [4].

One of the most significant advantages of 3D cell cultures is their ability to improve drug screening processes. Traditional 2D models often fail to predict how drugs will behave in the human body, leading to costly and time-consuming failures in clinical trials. In contrast, 3D cultures provide more reliable predictions of drug efficacy, absorption, and toxicity. These models allow researchers to test a wider range of compounds in a more physiologically relevant context, improving the chances of identifying viable drug candidates. Moreover, the ability to assess drugs' effects on the extracellular matrix, cell-to-cell interactions, and tumor microenvironments allows for more comprehensive toxicity testing [5].

The advent of personalized medicine is another area where 3D cell cultures have made a significant impact. By using patient-derived cells to create 3D models, researchers can better understand how an individual’s specific genetic makeup may influence their response to treatment. These patient-derived models are especially important for cancer research, where tumor heterogeneity plays a crucial role in treatment outcomes. By testing different drugs on 3D cultures derived from a patient’s own cells, clinicians can tailor treatments to the individual, improving the likelihood of a successful therapeutic outcome [6].

Stem cells have added a new dimension to 3D cell culture models, particularly in the creation of organoids. Pluripotent stem cells (iPSCs) can differentiate into various cell types and tissues, making them invaluable for studying disease mechanisms and drug responses. Stem cell-derived 3D models can replicate the complexity of human organs, providing more accurate models for drug discovery. These models are particularly useful for studying developmental diseases, genetic disorders, and neurodegenerative diseases, offering insights that were previously unattainable using traditional 2D cultures [7].

Cancer research has been one of the most promising fields to benefit from the use of 3D cell culture systems. Tumor spheroids and organoids can simulate the microenvironment of a tumor, including the hypoxic core and the outer proliferative layers. This enables a more accurate evaluation of how drugs penetrate tumors and their effects on different regions of the cancer mass. Additionally, 3D cultures allow for the investigation of cancer metastasis and drug resistance mechanisms, which are often not well represented in traditional 2D cultures. By providing a more realistic tumor model, researchers can accelerate the discovery of novel cancer therapies [8].

Despite the significant advancements in 3D cell culture technology, challenges remain. One major hurdle is the scalability of these models for high-throughput drug screening. While small-scale 3D cultures can be highly effective, scaling them up to accommodate the high number of compounds required for drug testing is technically challenging and expensive. Furthermore, while 3D models are closer to in vivo conditions, they still do not fully replicate the complexity of human organs, such as immune system interactions and vascular networks. Researchers are working to overcome these limitations by integrating more advanced techniques like microfluidics and organ-on-a-chip systems [9].

Looking ahead, the future of 3D cell culture systems in drug discovery is bright. Ongoing innovations in biomaterials, stem cell technology, and microfluidics are expected to further improve the accuracy and relevance of 3D models. Advances in automation and AI-driven analysis will also enable more efficient drug screening, allowing researchers to test more compounds in less time. As these technologies evolve, 3D cell cultures are poised to play an even more central role in the development of new drugs, bringing us closer to more effective, personalized therapies for a wide range of diseases [10].

Conclusion

3D cell culture systems represent a paradigm shift in drug discovery, offering more accurate and reliable models for testing drug efficacy, toxicity, and disease progression. With innovations in materials, stem cell technology, and patient-derived models, these systems are paving the way for more personalized and effective treatments. While challenges remain, the potential of 3D cultures to improve the drug discovery process and lead to breakthroughs in therapeutic development is undeniable. As technology continues to advance, the integration of 3D cell culture systems into mainstream drug discovery will revolutionize the pharmaceutical industry and the way we treat diseases.

References

  1. Lovitt CJ, Shelper TB, Avery VM. Cancer drug discovery: recent innovative approaches to tumor modeling. Expert Opin. Drug Discov. 2016;11(9):885-94.

    2. Indexed at, Google Scholar, Cross Ref

  2. Fang Y, Eglen RM. Three-dimensional cell cultures in drug discovery and development. SLAS Discov. 2017;22(5):456-72.

    3. Indexed at, Google Scholar, Cross Ref

  3. Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front. Pharmacol. 2018;9:6.

    4. Indexed at, Google Scholar, Cross Ref

  4. Rimann M, Graf-Hausner U. Synthetic 3D multicellular systems for drug development. Curr Opin Biotechnol. 2012;23(5):803-9.

    5. Indexed at, Google Scholar, Cross Ref

  5. Lv D, Hu Z, Lu L, et al. Three?dimensional cell culture: A powerful tool in tumor research and drug discovery. Oncol Lett. 2017;14(6):6999-7010.

    6. Indexed at, Google Scholar, Cross Ref

  6. Dave R, Pandey K, Patel R, et al. Biological Scaffolds in 3D Cell Models: Driving Innovation in Drug Discovery. Stem Cell Rev Rep. 2024:1-20.

    7. Indexed at, Google Scholar, Cross Ref

  7. Breslin S, O’Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today. 2013;18(5-6):240-9.

    8. Indexed at, Google Scholar, Cross Ref

  8. Ravi M, Paramesh V, Kaviya SR, et al. 3D cell culture systems: advantages and applications. J Cell Physiol. 2015;230(1):16-26.

    9. Indexed at, Google Scholar, Cross Ref

  9. Wu MH, Huang SB, Lee GB. Microfluidic cell culture systems for drug research. Lab Chip. 2010;10(8):939-56.

    10. Indexed at, Google Scholar, Cross Ref

  10. Moshksayan K, Kashaninejad N, Saidi MS. Inventions and innovations in preclinical platforms for cancer research. Inventions. 2018;3(3):43.

    11. Indexed at, Google Scholar, Cross Ref

Get the App